'On consolidated basis

Quarter ended September 2024 compared with Quarter ended September 2023.

Net sales (including other operating income) of Dr Reddys Laboratories has increased 16.45% to Rs 8038.2 crore.  Sales of Pharmaceutical Services segment has gone up 16.26% to Rs 1,119.00 crore (accounting for 13.48% of total sales).  Sales of Global Generics segment has gone up 17.19% to Rs 7,163.60 crore (accounting for 86.30% of total sales).  Sales of Others segment has gone down 73.79% to Rs 17.90 crore (accounting for 0.22% of total sales).  Inter-segment sales rose Rs 241.20 crore to Rs 262.30 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 18.32% to Rs 4,777.20 crore.  PBIT of Pharmaceutical Services segment rose 100.08% to Rs 252.10 crore (accounting for 5.28% of total PBIT).  PBIT of Global Generics segment rose 16.18% to Rs 4,516.20 crore (acco...

• 

  (22-Jan-2025)

  KEI Industries

  Sales up 20%, net up 9%

• 

  (22-Jan-2025)

  Dalmia Bharat

  PAT down 76.8% YoY to Rs 61 crore in Q3FY2025

• 

  (22-Jan-2025)

  Indiamart Intermesh

  Revenue up 16.05% YoY to Rs 354.3 crore in Q3FY2025

• 

  (22-Jan-2025)

  PNB Housing Finance

  AUM growth, asset quality and margin improves